Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the last 30 days include United Imaging Healthcare, Lens Technology, Aibo Medical, Sanhua Intelligent Control, and Zhaoyi Innovation [2][13] - In the last 5 days, the most popular companies for institutional research include Ninebot Company-WD, Rongbai Technology, Lens Technology, Yintong Intelligent Control, and Yinglian Co., Ltd [2][15] - Among the top twenty companies in the last 30 days, 19 companies had 10 or more rating agencies involved, with significant profit growth expected for Jiao Cheng Ultrasound, Lanke Technology, and United Imaging Healthcare in Q1-Q3 of 2025 compared to the same period in 2024 [2][13][16] Group 2: Major Shareholder Increase in A-Share Listed Companies - From November 17 to November 21, 2025, five listed companies announced significant shareholder increases, with Changshu Bank increasing its shareholding by more than 1% of total equity, while Huangtai Liquor, Longlide, Fuguang Co., and Feiwo Technology planned to increase their holdings with an average of more than 1% of the market value on the announcement date [3][20] - From January 1 to November 21, 2025, a total of 295 companies announced significant shareholder increases, with 90 of them having 10 or more rating agencies involved. Among these, 23 companies had an average planned increase amount exceeding 1% of the market value on the announcement date, including Xianhe Co., Hubei Yihua, Xinji Energy, and Zhongju Gaoxin [5][22] Group 3: Share Buyback Situation in A-Share Listed Companies - From November 17 to November 21, 2025, 65 companies announced their buyback progress, with 16 companies having 10 or more rating agencies involved. Five companies had an average planned buyback amount exceeding 1% of the market value on the announcement date, with a focus on Jian Sheng Group, Trina Solar, and Prologis Pharmaceuticals [4][25] - From January 1 to November 21, 2025, a total of 1,805 companies announced their buyback progress, with 344 of them having 10 or more rating agencies involved. Among these, 88 companies had a significant buyback ratio, with two companies, Huaming Equipment and Prologis Pharmaceuticals, still in the board proposal stage [6][27]

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

公告显示，头孢地尼干混悬剂，属于第三代口服头孢菌素类抗生素，适用于治疗由下列条件下的指定微 生物的敏感菌株引起的轻度至中度感染的儿童患者。急性细菌性中耳炎由流感嗜血杆菌(包括产生β-内 酰胺酶的菌株)、肺炎链球菌(仅对青霉素敏感的菌株)和卡他莫拉菌(包括产生β-内酰胺酶的菌株)引起。 咽炎/扁桃体炎由化脓性链球菌引起。单纯性皮肤和皮肤组织感染由金黄色葡萄球菌(包括产生β-内酰胺 酶的菌株)和化脓性链球菌引起。 普洛药业（000739）(000739.SZ)公告，公司全资子公司浙江普洛巨泰药业有限公司收到国家药品监督 管理局签发的头孢地尼干混悬剂(1.5g;3.0g)《药品注册证书》。 ...

公告显示，头孢地尼干混悬剂，属于第三代口服头孢菌素类抗生素，适用于治疗由下列条件下的指定微 生物的敏感菌株引起的轻度至中度感染的儿童患者。急性细菌性中耳炎由流感嗜血杆菌(包括产生β-内 酰胺酶的菌株)、肺炎链球菌(仅对青霉素敏感的菌株)和卡他莫拉菌(包括产生β-内酰胺酶的菌株)引起。 咽炎/扁桃体炎由化脓性链球菌引起。单纯性皮肤和皮肤组织感染由金黄色葡萄球菌(包括产生β-内酰胺 酶的菌株)和化脓性链球菌引起。 智通财经APP讯，普洛药业(000739.SZ)公告，公司全资子公司浙江普洛巨泰药业有限公司收到国家药品 监督管理局签发的头孢地尼干混悬剂(1.5g;3.0g)《药品注册证书》。 ...

格隆汇11月24日丨普洛药业(000739.SZ)公布，全资子公司浙江普洛巨泰药业有限公司收到国家药品监 督管理局（简称"药监局"）签发的头孢地尼干混悬剂（1.5g；3.0g）《药品注册证书》。头孢地尼干混 悬剂，属于第三代口服头孢菌素类抗生素，适用于治疗由下列条件下的指定微生物的敏感菌株引起的轻 度至中度感染的儿童患者。急性细菌性中耳炎由流感嗜血杆菌（包括产生β-内酰胺酶的菌株）、肺炎链 球菌（仅对青霉素敏感的菌株）和卡他莫拉菌（包括产生β-内酰胺酶的菌株）引起。咽炎/扁桃体炎由 化脓性链球菌引起。单纯性皮肤和皮肤组织感染由金黄色葡萄球菌（包括产生β-内酰胺酶的菌株）和化 脓性链球菌引起。 ...

Core Viewpoint - The company has received approval for its cephalosporin product, marking a significant milestone in its market strategy and potential for growth [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhejiang Pro Pharmaceutical Co., Ltd., has been granted a drug registration certificate for its cephalosporin dry suspension (1.5g; 3.0g) by the National Medical Products Administration [1] - This product is the first generic drug in China to be approved and deemed to have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Market Implications - The approval allows the product to qualify for participation in national medical insurance negotiations, which is expected to enhance its market sales and competitiveness [1] - The company may face uncertainties in production and sales due to potential changes in policies, regulations, and market conditions [1]

证券代码：000739 证券简称：普洛药业 公告编号：2025-71 普洛药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）全资子公司浙江普洛巨 泰药业有限公司收到国家药品监督管理局（以下简称"药监局"）签发的头孢地 尼干混悬剂（1.5g；3.0g）《药品注册证书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：头孢地尼干混悬剂 2、剂型：口服混悬剂 3、规格：1.5g（125mg/5ml）；3.0g（250mg/5ml） 4、注册分类：化学药品 3 类 5、上市许可持有人：浙江普洛巨泰药业有限公司 6、生产企业：浙江普洛巨泰药业有限公司 7、证书编号：2025S03414；2025S03415 8、药品批准文号：国药准字 H20255948；国药准字 H20255949 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 普洛药业股份有限公司董事会 二、药品其他相关情况 头孢地尼干混 ...

人民财讯11月24日电，普洛药业（000739）11月24日公告，全资子公司浙江普洛巨泰药业有限公司收到 国家药监局签发的头孢地尼干混悬剂药品注册证书。头孢地尼干混悬剂属于第三代口服头孢菌素类抗生 素，适用于治疗指定微生物的敏感菌株引起的轻度至中度感染的儿童患者。 ...

11月19日，普洛药业(000739.SZ)发布公告称，公司拟使用自有资金及金融机构回购贷款通过深圳 证券交易所交易系统以集中竞价交易方式回购公司股份，回购股份价格不超过人民币23元/股，回购资 金总额为不低于1.8亿元（含）且不超过3.6亿元（含）。 预计可回购股份数量为783万股—1565万股，约占公司总股本的0.68%—1.35%。回购期限为自董事 会审议通过回购股份方案之日起12个月内。 若公司在股份回购完成后36个月内未能实施前述用途，未使用部分将依法履行相关程序后予以注 销。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-70 普洛药业股份有限公司 关于 2025 年第二次回购股份报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1.普洛药业股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日召开 第九届董事会第十七次会议，经全体董事审议，一致通过了《关于 2025 年第二 次回购公司股份方案的议案》。根据《公司章程》的相关规定，本次回购股份方 案属于董事会审批权限范围，无需提交股东大会审议。 2.公司拟使用自有资金及金融机构回购贷款以集中竞价交易方式回购公司 股份，本次回购资金总额为人民币 18,000 万元—36,000 万元，本次回购股份价 格不超过人民币 23 元/股，未超过公司董事会通过回购股份决议前三十个交易日 公司股票交易均价的 150%。具体回购数量以回购期限届满或者回购股份实施完 毕时实际回购的股份数量为准。回购期限为自董事会审议通过回购股份方案之日 起 12 个月内。 3.公司已在中国证券登记结算公司深圳分公司开立了回购股份专用证券账 户。 4.截至本公告披 ...